BRPI0517204A - sulfato de levosalbutamol cristalino (forma i), sulfato de levosalbutamol cristalino (forma ii), sulfato de levosalbutamol cristalino (forma iii), processo para preparar a forma i do sulfato de levosalbutamol cristalino, processo para preparar a forma ii do sulfato de levosalbutamol cristalino, processo para preparar a forma iii do sulfato de levosalbutamol, composição farmacêutica, composto, combinação, pó seco para inalador, processo para preparar um pó seco para inalador, processo para preparar uma composição famacêutica, processo para fabricação de uma composição farmacêutica, método para tratamento de um mamìfero, e uso de uma combinação de salbutamol - Google Patents

sulfato de levosalbutamol cristalino (forma i), sulfato de levosalbutamol cristalino (forma ii), sulfato de levosalbutamol cristalino (forma iii), processo para preparar a forma i do sulfato de levosalbutamol cristalino, processo para preparar a forma ii do sulfato de levosalbutamol cristalino, processo para preparar a forma iii do sulfato de levosalbutamol, composição farmacêutica, composto, combinação, pó seco para inalador, processo para preparar um pó seco para inalador, processo para preparar uma composição famacêutica, processo para fabricação de uma composição farmacêutica, método para tratamento de um mamìfero, e uso de uma combinação de salbutamol

Info

Publication number
BRPI0517204A
BRPI0517204A BRPI0517204-7A BRPI0517204A BRPI0517204A BR PI0517204 A BRPI0517204 A BR PI0517204A BR PI0517204 A BRPI0517204 A BR PI0517204A BR PI0517204 A BRPI0517204 A BR PI0517204A
Authority
BR
Brazil
Prior art keywords
preparing
pharmaceutical composition
levosalbutamol sulfate
crystalline
sulfate
Prior art date
Application number
BRPI0517204-7A
Other languages
English (en)
Inventor
Amar Lulla
Geena Malhotra
Ramchandra Rao Dharmaraj
Rajendra Narayanrao Kankan
Alka Chaudhary
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of BRPI0517204A publication Critical patent/BRPI0517204A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SULFATO DE LEVOSALBUTAMOL CRISTALINO (FORMA I), SULFATO DE LEVOSALBUTAMOL CRISTALINO (FORMA II), SULFATO DE LEVOSALBUTAMOL CRISTALINO (FORMA III), PROCESSO PARA PREPARAR A FORMA I DO SULFATO DE LEVOSALBUTAMOL CRISTALINO, PROCESSO PARA PREPARAR A FORMA II DO SULFATO DE LEVOSALBUTAMOL CRISTALINO, PROCESSO PARA PREPARAR A FORMA III DO SULFATO DE LEVOSALBUTAMOL, COMPOSIçãO FARMACêUTICA, COMPOSTO, COMBINAçãO, Pó SECO PARA INALADOR, PROCESSO PARA PREPARAR UM Pó SECO PARA INALADOR, PROCESSO PARA PREPARAR UMA COMPOSIçAO FARMACêUTICA, PROCESSO PARA FABRICAçãO DE UMA COMPOSIçãO FARMACêUTICA, MéTODO PARA TRATAMENTO DE UM MAMìFERO E USO DE UMA COMBINAçãO DE SALBUTAMOL". A invenção provê três formas polimórficas do sulfato de levosalbutamol cristalino designado aqui como Forma (I) , Forma (II) e Forma (III) . A Forma I do sulfato de levosalbutamol cristalina é caracterizada por um padrão de pó XRD com picos em 10.8, 11.9, 13.0, 18.3, 28.5 <sym> 0.2 graus 2- Theta. A Forma II do sulfato de levosalbutamol cristalina é caracterizada por um padrão de pó XRD com picos em 8.7, 9.6, 15.2, 17.7, 19.1, 27.2, 30.7 <sym> 0.2 graus 2-Theta. A Forma III do sulfato de levosalbutamol cristalina é caracterizada por um padrão de pó XRD com picos em 5.5, 6.9, 7.3, 18.7 <sym> 0.2 graus 2-Theta. O processo para preparar as novas formas polimórficas e as composições farmacêuticas compreendendo-as também é provido. Uma composição farmacêutica compreende um isómero terapeuticamente eficaz do salbutamol ou um sal, solvato, éster, derivado ou polimorfo do mesmo, um glicocorticóide e um veículo farmaceuticamente aceitável ou um excipiente e, opcionalmente, um ou mais de outros agentes terapêuticos. Preferivelmente, a composição é uma formulação aerossol compreendendo o fármaco, um propelente e, opcionalmente, um ou mais de outros ingredientes, tais como um surfactante, co-solvente, ou agente avolumador. Alternativamente, suspensões DPI ou de inalação podem ser utilizadas.
BRPI0517204-7A 2004-12-17 2005-12-19 sulfato de levosalbutamol cristalino (forma i), sulfato de levosalbutamol cristalino (forma ii), sulfato de levosalbutamol cristalino (forma iii), processo para preparar a forma i do sulfato de levosalbutamol cristalino, processo para preparar a forma ii do sulfato de levosalbutamol cristalino, processo para preparar a forma iii do sulfato de levosalbutamol, composição farmacêutica, composto, combinação, pó seco para inalador, processo para preparar um pó seco para inalador, processo para preparar uma composição famacêutica, processo para fabricação de uma composição farmacêutica, método para tratamento de um mamìfero, e uso de uma combinação de salbutamol BRPI0517204A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1356MU2004 2004-12-17
IN40MU2005 2005-01-14
IN343MU2005 2005-03-24
PCT/GB2005/004935 WO2006064283A1 (en) 2004-12-17 2005-12-19 Pharmaceutical compounds and compositions

Publications (1)

Publication Number Publication Date
BRPI0517204A true BRPI0517204A (pt) 2008-09-30

Family

ID=36091333

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517204-7A BRPI0517204A (pt) 2004-12-17 2005-12-19 sulfato de levosalbutamol cristalino (forma i), sulfato de levosalbutamol cristalino (forma ii), sulfato de levosalbutamol cristalino (forma iii), processo para preparar a forma i do sulfato de levosalbutamol cristalino, processo para preparar a forma ii do sulfato de levosalbutamol cristalino, processo para preparar a forma iii do sulfato de levosalbutamol, composição farmacêutica, composto, combinação, pó seco para inalador, processo para preparar um pó seco para inalador, processo para preparar uma composição famacêutica, processo para fabricação de uma composição farmacêutica, método para tratamento de um mamìfero, e uso de uma combinação de salbutamol

Country Status (11)

Country Link
US (1) US20090263333A1 (pt)
EP (2) EP2311793A1 (pt)
JP (1) JP2008524195A (pt)
KR (1) KR20070100735A (pt)
AU (1) AU2005315337B2 (pt)
BR (1) BRPI0517204A (pt)
CA (1) CA2591406A1 (pt)
IL (1) IL183986A0 (pt)
MX (1) MX2007007378A (pt)
NZ (1) NZ555500A (pt)
WO (1) WO2006064283A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1809243T4 (da) 2004-07-02 2022-09-05 Boehringer Ingelheim Int Aerosolsuspensionsformuleringer med tg 227 ea som drivmiddel
DE102006017320A1 (de) * 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
US20070282010A1 (en) 2006-05-30 2007-12-06 Bridge Pharma, Inc. Methods of Accelerating Muscle Growth, Decreasing Fat Deposits and Improving Feed Efficiency in Livestock Animals
CN101909652A (zh) * 2007-11-07 2010-12-08 阿斯利康(瑞典)有限公司 含有抗坏血酸衍生物的干粉制剂
US7723392B2 (en) 2007-12-03 2010-05-25 Bridge Pharma, Inc. Use of RR/SR-ractopamine
PT105058B (pt) * 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
IT1399912B1 (it) * 2010-04-29 2013-05-09 Lundbeck Pharmaceuticals Italy S Pa Processo di preparazione di ritodrina cloridrato.
BR112014002593B1 (pt) * 2011-08-02 2022-11-29 Alfasigma S.p.A Composição farmacêutica de avidina oxidada apropriada para inalação e kits relacionados
WO2013140120A1 (en) * 2012-03-22 2013-09-26 Cipla Limited Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole
DK2897589T3 (en) 2013-11-22 2018-03-12 Teva Branded Pharmaceutical Prod R & D Inc Inhalable drug
TN2016000259A1 (en) 2016-06-27 2017-10-06 Rekik Raouf Salbutamol (albuterol) eye protective medicament.
WO2019031902A2 (ko) 2017-08-11 2019-02-14 (주)아모레퍼시픽 (r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1291A (en) 1980-02-15 1985-10-18 Glaxo Group Ltd Androstane 17 beta carbothioates
US5362755A (en) 1990-01-05 1994-11-08 Sepracor, Inc. Method for treating asthma using optically pure (R)-albuterol
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
US5545745A (en) 1994-05-23 1996-08-13 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
US6013245A (en) * 1995-01-26 2000-01-11 Glaxo Group Limited Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant
SK284448B6 (sk) * 1995-04-14 2005-04-01 Glaxo Wellcome Inc. Merací dávkovací inhalátor
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
CN1144582C (zh) * 2000-11-28 2004-04-07 中国药科大学 治疗呼吸系统疾病的无氟里昂药用气雾剂
GB0030171D0 (en) * 2000-12-11 2001-01-24 Cipla Ltd Process for preparing isomers of salbutamol
NO315264B1 (no) * 2001-01-23 2003-08-11 Tomra Systems Asa Deteksjonssystem
US6702997B2 (en) * 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
CN100432044C (zh) 2002-09-13 2008-11-12 苏州君宁新药开发中心有限公司 左旋沙丁胺醇制备新工艺
DK2292584T3 (en) 2002-12-10 2017-05-01 Sunovion Pharmaceuticals Inc Pharmaceutical composition comprising levalbuterol L-hemitartrate salt as aerosol formulation

Also Published As

Publication number Publication date
AU2005315337B2 (en) 2012-07-05
US20090263333A1 (en) 2009-10-22
AU2005315337A1 (en) 2006-06-22
EP2311793A1 (en) 2011-04-20
WO2006064283A1 (en) 2006-06-22
NZ555500A (en) 2010-09-30
KR20070100735A (ko) 2007-10-11
JP2008524195A (ja) 2008-07-10
IL183986A0 (en) 2007-10-31
CA2591406A1 (en) 2006-06-22
MX2007007378A (es) 2007-08-14
EP1828100A1 (en) 2007-09-05

Similar Documents

Publication Publication Date Title
BRPI0517204A (pt) sulfato de levosalbutamol cristalino (forma i), sulfato de levosalbutamol cristalino (forma ii), sulfato de levosalbutamol cristalino (forma iii), processo para preparar a forma i do sulfato de levosalbutamol cristalino, processo para preparar a forma ii do sulfato de levosalbutamol cristalino, processo para preparar a forma iii do sulfato de levosalbutamol, composição farmacêutica, composto, combinação, pó seco para inalador, processo para preparar um pó seco para inalador, processo para preparar uma composição famacêutica, processo para fabricação de uma composição farmacêutica, método para tratamento de um mamìfero, e uso de uma combinação de salbutamol
ES2393230T3 (es) Uso farmacéutico de amidas sustituidas
BR0212468A (pt) Compoto de uréia ativos como antagonistas de receptor de vanilóides para o tratamento de dor
ES2786374T3 (es) Compuesto antimicótico
AR032335A1 (es) Polimorfos del compuesto triazolo [4,5-d] pirimidina, una mezcla, proceso para su preparacion, composicion farmaceutica, y uso de estos compuestos para la fabricacion de medicamentos
TW200745111A (en) New compounds
NO20075042L (no) Farmasoytisk sammensetning innbefattende en omega-karboksyarylsubstituert difenylurea for behandling av cancer
CZ304294B6 (cs) Léčivo a farmaceutická souprava
UA73804C2 (en) Anticholinergic agents being used as medicaments, a method for the preparation thereof and a pharmaceutical composition
UY33494A (es) Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen
BR0317645A (pt) Composto ou um sal deste, composição farmacêutica, uso de um composto, e, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deterioração cognitiva em um mamìfero
BR0110419A (pt) Esteróides de 3-nitrogênio-6,7-dioxigênio e usos relacionados aos mesmos
TW200607807A (en) Macrocyclic beta-secretase inhibitors
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
JP2007522162A5 (pt)
BR0317294A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários
BR0015908A (pt) Emprego de compostos org nicos no tratamento de doenças
RS51585B (en) AEROSOLIC INHALATION FORMULATION CONTAINING ANTICHOLINERGIC
HRP20211762T1 (hr) Derivati benzoksaborola za liječenje bakterijskih infekcija
EP3074398B1 (en) A3 adenosine receptor agonists
BR0308133A (pt) Forma polimórfica cristalina de cloridrato de irinotecan
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
RU2013104401A (ru) Фармацевтический препарат, содержащий ингибитор фосфодиэстеразы
JP2008524195A5 (pt)
JP2017513824A5 (pt)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.